New hope for advanced breast cancer: experimental drug ARX788 tested after other treatments fail
NCT ID NCT04829604
First seen Nov 16, 2025 · Last updated May 22, 2026 · Updated 20 times
Summary
This phase 2 study tests an experimental drug called ARX788 in 72 adults with HER2-positive metastatic breast cancer who have already been treated with a drug called T-DXd. The main goal is to see how many patients' tumors shrink or disappear. Participants must have measurable tumors and have had no more than 5 prior treatments for advanced disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE METASTATIC BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Los Angeles, California, 90033, United States
-
Research Site
Newport Beach, California, 92663, United States
-
Research Site
San Francisco, California, 94158, United States
-
Research Site
Whittier, California, 90602, United States
-
Research Site
Atlanta, Georgia, 30322, United States
-
Research Site
Chicago, Illinois, 60611, United States
-
Research Site
Louisville, Kentucky, 40207, United States
-
Research Site
Silver Spring, Maryland, 20904, United States
-
Research Site
Boston, Massachusetts, 02215, United States
-
Research Site
St Louis, Missouri, 63110, United States
-
Research Site
Omaha, Nebraska, 68130, United States
-
Research Site
Las Vegas, Nevada, 89128, United States
-
Research Site
Camden, New Jersey, 08103, United States
-
Research Site
New Hyde Park, New York, 11042, United States
-
Research Site
New York, New York, 10028, United States
-
Research Site
Shirley, New York, 11967, United States
-
Research Site
The Bronx, New York, 10469, United States
-
Research Site
Portland, Oregon, 97213, United States
-
Research Site
Tigard, Oregon, 97223, United States
-
Research Site
Philadelphia, Pennsylvania, 19104, United States
-
Research Site
Dallas, Texas, 75246, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
San Antonio, Texas, 78229, United States
-
Research Site
Norfolk, Virginia, 23502, United States
-
Research Site
Tacoma, Washington, 98405, United States
-
Research Site
Frankston, Victoria, 3199, Australia
-
Research Site
Geelong, Victoria, 3220, Australia
-
Research Site
Nedlands, Western Australia, 6009, Australia
-
Research Site
Daegu, 42601, South Korea
-
Research Site
Seongnam-si, 13620, South Korea
-
Research Site
Seoul, 02841, South Korea
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 05505, South Korea
Conditions
Explore the condition pages connected to this study.